Halozyme Therapeutics, Inc. (HALO): Gross Profit
$1.17B
Year ended 2025-12-31
$1.37B
Trailing 12 months to 2026-06-30
+30.9%
3-year compound annual growth
+39.1%
5-year compound annual growth
+27.1%
10-year compound annual growth
| Period ended | Gross Profit | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.17B | +36.4% | 2026-02-17, From 2025-01-01 |
| 2024-12-31 | $855.91M | +34.4% | 2026-02-17, From 2024-01-01 |
| 2023-12-31 | $636.89M | +22.3% | 2026-02-17, From 2023-01-01 |
| 2022-12-31 | $520.81M | +43.9% | 2025-02-18, From 2022-01-01 |
| 2021-12-31 | $361.90M | +61.4% | 2024-02-20, From 2021-01-01 |
| 2020-12-31 | $224.23M | +49.0% | 2023-02-21, From 2020-01-01 |
| 2019-12-31 | $150.45M | +6.2% | 2022-02-22, From 2019-01-01 |
| 2018-12-31 | $141.73M | -50.4% | 2021-02-23, From 2018-01-01 |
| 2017-12-31 | $285.46M | +151.5% | 2020-02-24, From 2017-01-01 |
| 2016-12-31 | $113.48M | +7.3% | 2019-02-21, From 2016-01-01 |
| 2015-12-31 | $105.81M | +101.2% | 2018-02-20, From 2015-01-01 |
| 2014-12-31 | $52.60M | +8.3% | 2017-02-28, From 2014-01-01 |
| 2013-12-31 | $48.55M | n/a | 2016-02-29, From 2013-01-01 |
| No annual figure between 2010-12-31 and 2013-12-31. | |||
| 2010-12-31 | $12.64M | n/a | 2013-03-01, From 2010-01-01 |
Gross Profit at similar companies
| Company | Year ended | Gross Profit | Change YoY |
|---|---|---|---|
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $1.17B | +36.4% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $799.07M | +1.1% |
| Novavax Inc (NVAX) | 2025-12-31 | $1.05B | +119.1% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $1.08B | -39.3% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $1.30B | +34.3% |
| Repligen Corp (RGEN) | 2025-12-31 | $386.25M | +40.6% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $292.76M | +33.3% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | $191.00M | +43.2% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $205.62M | +92.4% |
Compare HALO, TECH, NVAX, MRNA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗